Volanesorsen and triglyceride levels in familial chylomicronemia syndrome

New England Journal of Medicine Aug 13, 2019

Witztum JL, Gaudet D, Freedman SD, et al. - Researchers evaluated the safety and efficacy of volanesorsen in a phase 3, double-blind, randomized, 52-week trial. The study sample consisted of 66 patients with familial chylomicronemia syndrome who were randomized in a 1:1 ratio to receive volanesorsen or placebo. Volanesorsen treatment reduced triglyceride levels to < 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome. Adverse events commonly encountered included thrombocytopenia and injection-site reactions.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay